よむ、つかう、まなぶ。
Global Health Vision of Ministry of Health, Labour and Welfare of Japan (23 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_42939.html |
| 出典情報 | 「厚生労働省国際保健ビジョン」の公表について（8／26）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
industries utilizing procurement frameworks of international organizations will continue
in the fiscal year 2024 through private enterprises.
(5) Strategies to ensure a stable supply of pharmaceuticals as economic security
① Purpose
In March 2019, a serious issue occurred due to prolonged supply disruption of
cephazolin, an antimicrobial drug with a high dependence on active pharmaceutical
ingredients (APIs) from China. The supply issues, stemming from manufacturing
troubles in China, had a significant impact on the smooth provision of medical care in
Japan.
In light of this background, the “Act on the Promotion of Ensuring National Security
through Integrated Implementation of Economic Measures” enacted in May 2022
designates antimicrobial drugs among the 8 Stably Secured Pharmaceuticals as
specified critical products under the Act, along with efforts to promote diversification
of supply sources of APIs for other pharmaceutical products, In addition to efforts to
promote diversification of supply sources of APIs for other drugs, a system to supply
products to medical facilities without interruption even when supply of APIs from
overseas is disrupted should be established.
② Contents
Regarding antimicrobial drugs, which are specified critical products, domestically
produced APIs are expected to be more expensive than those produced overseas.
The increased cost is anticipated to reduce the profitability for manufactures. For this
reason, in the second supplementary budget for FY2022, ¥55.3 billion has been
allocated for domestication of antimicrobial APIs, covering part of the costs associated
with constructing manufacturing facilities and other related expenses.
In addition, it is necessary to create an environment in which domestically
manufactured APIs can be used continuously in the production of antimicrobial drugs
during normal times. We will comprehensively consider various issues, including
trends in the price differences between domestic and foreign APIs, the structure of
support measures including its operation cost, and the feasibility of support measures.
For pharmaceuticals other than specified critical products, we have been
8
The Ministry of Health, Labour and Welfare (MHLW) has selected these drugs as those that are necessary
for the seamless provision of medical care to protect the lives of the people in terms of Japan's
security, and for which special consideration is required to ensure stability.
23
in the fiscal year 2024 through private enterprises.
(5) Strategies to ensure a stable supply of pharmaceuticals as economic security
① Purpose
In March 2019, a serious issue occurred due to prolonged supply disruption of
cephazolin, an antimicrobial drug with a high dependence on active pharmaceutical
ingredients (APIs) from China. The supply issues, stemming from manufacturing
troubles in China, had a significant impact on the smooth provision of medical care in
Japan.
In light of this background, the “Act on the Promotion of Ensuring National Security
through Integrated Implementation of Economic Measures” enacted in May 2022
designates antimicrobial drugs among the 8 Stably Secured Pharmaceuticals as
specified critical products under the Act, along with efforts to promote diversification
of supply sources of APIs for other pharmaceutical products, In addition to efforts to
promote diversification of supply sources of APIs for other drugs, a system to supply
products to medical facilities without interruption even when supply of APIs from
overseas is disrupted should be established.
② Contents
Regarding antimicrobial drugs, which are specified critical products, domestically
produced APIs are expected to be more expensive than those produced overseas.
The increased cost is anticipated to reduce the profitability for manufactures. For this
reason, in the second supplementary budget for FY2022, ¥55.3 billion has been
allocated for domestication of antimicrobial APIs, covering part of the costs associated
with constructing manufacturing facilities and other related expenses.
In addition, it is necessary to create an environment in which domestically
manufactured APIs can be used continuously in the production of antimicrobial drugs
during normal times. We will comprehensively consider various issues, including
trends in the price differences between domestic and foreign APIs, the structure of
support measures including its operation cost, and the feasibility of support measures.
For pharmaceuticals other than specified critical products, we have been
8
The Ministry of Health, Labour and Welfare (MHLW) has selected these drugs as those that are necessary
for the seamless provision of medical care to protect the lives of the people in terms of Japan's
security, and for which special consideration is required to ensure stability.
23